Cargando…

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis

Human epidermal growth factor receptor 1 or 2 (HER1/2), and fibroblast growth factor receptor 1 (FGFR1) signaling serve critical roles in the progression of breast cancer; however, cross-talk between HER1/2 and FGFR1 signaling has not been extensively studied. In the present study, the copy number v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shinan, Qiu, Yan, Guo, Peng, Pu, Tianjie, Feng, Ye, Bu, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950032/ https://www.ncbi.nlm.nih.gov/pubmed/29805554 http://dx.doi.org/10.3892/ol.2018.8423

Ejemplares similares

Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
por: Guo, Peng, et al.
Publicado: (2017)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Working together for the family: determination of HER oncogene co-amplifications in breast cancer
por: Laurito, Sergio, et al.
Publicado: (2020)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
por: Luoh, Shiuh-Wen, et al.
Publicado: (2013)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer
por: Sellahewa, Chaminda, et al.
Publicado: (2008)

Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
por: Chen, Chin-Yau, et al.
Publicado: (2016)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
por: Dupouy, Diego G., et al.
Publicado: (2016)

Reduced Expression of KRT17 Predicts Poor Prognosis in HER2(high) Breast Cancer
por: Tang, Shasha, et al.
Publicado: (2022)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

FGFR1 amplification and the progression of non-invasive to invasive breast cancer
por: Gru, Alejandro A, et al.
Publicado: (2012)

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
por: Zheng, Hui, et al.
Publicado: (2019)

High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis
por: Nair, Madhumathy G, et al.
Publicado: (2021)

High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer
por: Amirfallah, Arsalan, et al.
Publicado: (2019)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
por: Burky, Matthew J, et al.
Publicado: (2020)

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
por: Stahl, Phillip, et al.
Publicado: (2015)

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2015)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0rv88nsb9lh8aha18hu3beu9le